NCT02414139 2024-03-20Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)NovartisPhase 2 Completed373 enrolled 34 charts 5 FDA
NCT01610336 2021-04-08A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi TreatmentNovartisPhase 2 Completed161 enrolled 32 charts
NCT02276027 2020-12-16A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung CancerNovartisPhase 2 Completed66 enrolled 18 charts